137 related articles for article (PubMed ID: 31967398)
1. Development of an automated micropipette coating method for drug-coated balloons.
Fuglsby K; Anderson JA; Engebretson D; Lamichhane S
J Biomed Mater Res B Appl Biomater; 2020 Jul; 108(5):2258-2275. PubMed ID: 31967398
[TBL] [Abstract][Full Text] [Related]
2. In vitro particulate and in vivo drug retention study of a novel polyethylene oxide formulation for drug-coated balloons.
Anderson JA; Lamichhane S; Vierhout T; Sherman A; Engebretson D; Pohlson K; Remund T; Kelly P
J Vasc Surg; 2018 May; 67(5):1537-1545.e7. PubMed ID: 28843789
[TBL] [Abstract][Full Text] [Related]
3. Development of drug-coated balloon for the treatment of multiple peripheral artery segments.
Anderson JA; Lamichhane S; Fuglsby K; Remund T; Pohlson K; Evans R; Engebretson D; Kelly P
J Vasc Surg; 2020 May; 71(5):1750-1757.e7. PubMed ID: 31519510
[TBL] [Abstract][Full Text] [Related]
4. Coating and Pharmacokinetic Evaluation of Air Spray Coated Drug Coated Balloons.
Turner EA; Atigh MK; Erwin MM; Christians U; Yazdani SK
Cardiovasc Eng Technol; 2018 Jun; 9(2):240-250. PubMed ID: 29497966
[TBL] [Abstract][Full Text] [Related]
5. Studying the effect of drug-to-excipient ratio on drug release profile for drug coated balloons.
Woolford S; Tran M; Yoda C; Oktem B; NguyenPho A; McDermott M; Wickramasekara S
Int J Pharm; 2022 May; 620():121749. PubMed ID: 35427748
[TBL] [Abstract][Full Text] [Related]
6. Preparation, characterization, in vitro drug release, and cellular interactions of tailored paclitaxel releasing polyethylene oxide films for drug-coated balloons.
Anderson JA; Lamichhane S; Remund T; Kelly P; Mani G
Acta Biomater; 2016 Jan; 29():333-351. PubMed ID: 26432441
[TBL] [Abstract][Full Text] [Related]
7. Pre-Clinical Investigation of Keratose as an Excipient of Drug Coated Balloons.
Goel E; Erwin M; Cawthon CV; Schaff C; Fedor N; Rayl T; Wilson O; Christians U; Register TC; Geary RL; Saul J; Yazdani SK
Molecules; 2020 Mar; 25(7):. PubMed ID: 32244375
[TBL] [Abstract][Full Text] [Related]
8. Optimization of balloon coating process for paclitaxel coated balloons via micro-pipetting method.
Woolford SE; Tran M; NguyenPho A; McDermott MK; Oktem B; Wickramasekara S
Int J Pharm; 2019 Jan; 554():312-321. PubMed ID: 30395954
[TBL] [Abstract][Full Text] [Related]
9. Hydrophilic Coating Microstructure Mediates Acute Drug Transfer in Drug-Coated Balloon Therapy.
Shazly T; Eberth JF; Kostelnik CJ; Uline MJ; Chitalia VC; Spinale FG; Alshareef A; Kolachalama VB
ACS Appl Bio Mater; 2024 May; 7(5):3041-3049. PubMed ID: 38661721
[TBL] [Abstract][Full Text] [Related]
10. Intrinsic coating morphology modulates acute drug transfer in drug-coated balloon therapy.
Chang GH; Azar DA; Lyle C; Chitalia VC; Shazly T; Kolachalama VB
Sci Rep; 2019 May; 9(1):6839. PubMed ID: 31048704
[TBL] [Abstract][Full Text] [Related]
11. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
Krishnan P; Faries P; Niazi K; Jain A; Sachar R; Bachinsky WB; Cardenas J; Werner M; Brodmann M; Mustapha JA; Mena-Hurtado C; Jaff MR; Holden AH; Lyden SP
Circulation; 2017 Sep; 136(12):1102-1113. PubMed ID: 28729250
[TBL] [Abstract][Full Text] [Related]
12. Sustainable Antirestenosis Effect With a Low-Dose Drug-Coated Balloon: The ILLUMENATE European Randomized Clinical Trial 2-Year Results.
Brodmann M; Werner M; Meyer DR; Reimer P; Krüger K; Granada JF; Jaff MR; Schroeder H;
JACC Cardiovasc Interv; 2018 Dec; 11(23):2357-2364. PubMed ID: 30522663
[TBL] [Abstract][Full Text] [Related]
13. The Ranger drug-coated balloon: advances in drug-coated technology for treatment of femoropopliteal segment arterial disease.
Sharma N; Finn MT; Parikh SA; Granada J
Future Cardiol; 2023 Mar; 19(3):127-135. PubMed ID: 37334764
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.
Caradu C; Lakhlifi E; Colacchio EC; Midy D; Bérard X; Poirier M; Ducasse E
J Vasc Surg; 2019 Sep; 70(3):981-995.e10. PubMed ID: 31126769
[TBL] [Abstract][Full Text] [Related]
15.
Turner E; Erwin M; Atigh M; Christians U; Saul JM; Yazdani SK
Front Pharmacol; 2018; 9():808. PubMed ID: 30104972
[No Abstract] [Full Text] [Related]
16. Critical appraisal of paclitaxel balloon angioplasty for femoral-popliteal arterial disease.
Herten M; Torsello GB; Schönefeld E; Stahlhoff S
Vasc Health Risk Manag; 2016; 12():341-56. PubMed ID: 27621646
[TBL] [Abstract][Full Text] [Related]
17. Correlating coating characteristics with the performance of drug-coated balloons--a comparative in vitro investigation of own established hydrogel- and ionic liquid-based coating matrices.
Kaule S; Minrath I; Stein F; Kragl U; Schmidt W; Schmitz KP; Sternberg K; Petersen S
PLoS One; 2015; 10(3):e0116080. PubMed ID: 25734818
[TBL] [Abstract][Full Text] [Related]
18. Ultrasound controlled paclitaxel releasing system-A novel method for improving the availability of coronary artery drug coated balloon.
Song C; Zhou C; Zhang J; Feng X; Cui X; Zhang F; Ma J; Toft ES; Ge J; Zhang H
Catheter Cardiovasc Interv; 2020 Aug; 96(2):E119-E128. PubMed ID: 31659805
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
Tepe G; Schroeder H; Albrecht T; Reimer P; Diehm N; Baeriswyl JL; Brechtel K; Speck U; Zeller T
J Endovasc Ther; 2020 Apr; 27(2):276-286. PubMed ID: 32096451
[No Abstract] [Full Text] [Related]
20. Stellarex drug-coated balloon: a technology evaluation.
Nerla R; Castriota F; Cremonesi A; Micari A
Expert Opin Drug Deliv; 2020 Sep; 17(9):1181-1188. PubMed ID: 32615811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
